biostudies-literatureRuggenenti PNIAID NIH HHS850-63https://www.ebi.ac.uk/biostudies/studies/S-EPMC3968490biostudies-literatureUnknown25(4)The outcome of steroid-dependent or frequently relapsing nephrotic syndrome of minimal change disease (MCD), mesangial proliferative GN (MesGN), or FSGS may be poor and with major treatment toxicity. This academic, multicenter, off-on trial (ClinicalTrials.gov #NCT00981838) primarily evaluated the effects of rituximab therapy followed by immunosuppression withdrawal on disease recurrence in 10 children and 20 adults with MCD/MesGN (n=22) or FSGS who had suffered ≥2 recurrences over the previous year and were in steroid-induced remission for ≥1 month. Participants received one dose (n=28) or two doses of rituximab (375 mg/m(2) intravenously). At 1 year, all patients were in remission: 18 were treatment-free and 15 never relapsed. Compared with the year before rituximab treatment, total relaJournal of the American Society of Nephrology : JASNRituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome.PMC3968490T32 AI078892Zennaro CRuggiero BPicconi PPastore SScordari AAbbate MMassella LRubis NBoccardo PRituximab in Nephrotic Syndrome of Steroid-Dependent or Frequently Relapsing Minimal Change Disease Or Focal Segmental Glomerulosclerosis (NEMO) Study GroupPrandini SVivarelli MRudnicki MPeracchi SMarasa MPennesi MCravedi PCarminati SPerna ARemuzzi GMele AAPisani ARuggenenti PCarraro MPisani GCapasso GGaspari FChianca AVilla APollastro RMMartinetti DCarrara FDiadei OEne-Iordache BGrimaldi RLecchi VEmma FDi Iorio AVisciano BCella CSabatella MfalseRituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome.The outcome of steroid-dependent or frequently relapsing nephrotic syndrome of minimal change disease (MCD), mesangial proliferative GN (MesGN), or FSGS may be poor and with major treatment toxicity. This academic, multicenter, off-on trial (ClinicalTrials.gov #NCT00981838) primarily evaluated the effects of rituximab therapy followed by immunosuppression withdrawal on disease recurrence in 10 children and 20 adults with MCD/MesGN (n=22) or FSGS who had suffered ≥2 recurrences over the previous year and were in steroid-induced remission for ≥1 month. Participants received one dose (n=28) or two doses of rituximab (375 mg/m(2) intravenously). At 1 year, all patients were in remission: 18 were treatment-free and 15 never relapsed. Compared with the year before rituximab treatment, total rela2014-01-01T00:00:00Z2014 Apr2026-04-16T05:01:40.067Z2026-04-07T14:06:01.065ZS-EPMC39684902448082410.1681/ASN.201303025110.1681/asn.2013030251